| Literature DB >> 34893092 |
Isobel C O'Sullivan1, Kay M Crossley2, Steven J Kamper3,4, Marienke van Middelkoop5, Bill Vicenzino1, Melinda M Franettovich Smith1, Hylton B Menz6, Anne J Smith7, Kylie Tucker8, Karina T O'Leary9,10, Nathalia Costa1, Natalie J Collins11,12.
Abstract
BACKGROUND: Patellofemoral pain (PFP) affects one-third of adolescents and can persist into adulthood, negatively impacting health and quality of life. Foot orthoses are a recommended treatment for adults with PFP, but have not been evaluated in adolescents. The primary objective was to determine the feasibility of conducting a full-scale randomised controlled trial (RCT) evaluating effects of contoured, prefabricated foot orthoses on knee pain severity and patient-perceived global change, compared to flat insoles. The secondary objective was to describe outcomes on a range of patient-reported outcome measures.Entities:
Keywords: Adolescents; Feasibility; Foot orthoses; Patellofemoral pain; Physiotherapy
Mesh:
Year: 2021 PMID: 34893092 PMCID: PMC8661346 DOI: 10.1186/s13047-021-00498-0
Source DB: PubMed Journal: J Foot Ankle Res ISSN: 1757-1146 Impact factor: 2.303
Fig. 1Participant flow through the study. *COVID-19 loss to follow-up refers to those whose participation in the trial was affected by COVID-19 restrictions
Baseline characteristics of participants. Values are mean (SD) unless otherwise indicated
| Characteristics | Contoured foot orthoses ( | Flat shoe insoles ( | Total ( |
|---|---|---|---|
| Age (years), median [IQR] | 14 [5] | 17 [3] | 15 [4] |
| Number (%) of females | 12 (71) | 15 (79) | 27 (75) |
| Height (cm) | 165 (9) | 169 (12) | 167 (10) |
| Body mass (kg) | 58.5 (12.1) | 60.8 (14.4) | 59.7 (13.3) |
| Number (%) with bilateral knee pain | 11 (65) | 10 (53) | 21 (58) |
| Duration of knee pain months, median [IQR] | 9 [38] | 24 [18] | 18.5 [29.5] |
| Average pain severity^, median [IQR] | 50 [24] | 50 [40] | 50 [34] |
| Worst pain severity^, median [IQR] | 70 [32] | 70 [37] | 70 [21] |
| Most painful activity in the last week, count (%): | |||
| squatting | 5 (29) | 6 (32) | 11 (30.5) |
| running | 6 (35) | 5 (26) | 11 (30.5) |
| walking upstairs | 4 (24) | 4 (21) | 8 (22) |
| walking downstairs | 2 (12) | 1 (5) | 3 (8) |
| walking | 0 (0) | 2 (11) | 2 (6) |
| jumping | 0 (0) | 1 (5) | 1 (3) |
^Measured on a 100 mm visual analogue scale (0 = no pain, 100 mm = worst pain imaginable), during their nominated most aggravating activity in the past week
IQR interquartile range
Fig. 2Credibility and Expectancy Questionnaire data at baseline and 2nd physiotherapy appointment. Left whisker: quartile 1; pink box: quartile 2; black line: median; blue box: quartile 3; right whisker: quartile 4
Secondary outcome measures at baseline, 6 weeks and 3 months (mean (SD) unless otherwise stated)
| Contoured foot orthoses ( | Flat shoe insoles ( | |||||
|---|---|---|---|---|---|---|
| Baseline | 6 weeks | 3 months | Baseline | 6 weeks | 3 months | |
| Average pain severity [0-100 mm] | 47.7 (16.1) | 46.1 (21.7) | 38.1 (21.2) | 47.5 (23.2) | 40.6 (23.5) | 33.4 (20.7) |
| Worst pain severity [0-100 mm] | 63.8 (16.7) | 60 (23) | 47.9 (23.8) | 57.9 (24.4) | 51.8 (28.8) | 42.7 (24.1) |
| GROC, | ||||||
| | – | 0 (0) | 1 (6.5) | – | 0 (0) | 0 (0) |
| | – | 4 (33) | 8 (53.5) | – | 3 (27.3) | 4 (36) |
| | – | 5 (42) | 4 (27) | – | 3 (27.3) | 5 (46) |
| | – | 2 (17) | 1 (6.5) | – | 3 (27.3) | 2 (18) |
| | – | 0 (0) | 0 (0) | – | 1 (9) | 0 (0) |
| | – | 1 (8) | 1 (6.5) | – | 1 (9) | 0 (0) |
| Number (%) responding ‘yes’ to Patient Acceptable Symptom State | 12 (71) | 9 (75) | 13 (87) | 13 (68) | 7 (64) | 8 (73) |
| KOOS-Child [100–0] | ||||||
| | 63.4 (10.6) | 66.7 (14.4) | 81.3 (12.3) | 63.5 (16.8) | 68.2 (19.1) | 79 (13.7) |
| | 77.5 (9.9) | 77.1 (13.4) | 88.5 (10.1) | 75.4 (13.2) | 77.6 (12.7) | 84.7 (12.1) |
| | 82.2 (9.5) | 86.4 (10.6) | 94 (6.5) | 79.1 (14.5) | 87.2 (9.7) | 93.8 (7) |
| | 62.4 (16.5) | 69.3 (23.4) | 81.6 (17.4) | 62.2 (20.3) | 72.1 (25.4) | 87.3 (16.3) |
| | 57.1 (17.1) | 61.1 (20.6) | 78 (17.8) | 52.9 (18.5) | 64 (20) | 75.4 (18.5) |
| KOOS-PF [100–0] | 60.6 (15.8) | 65.1 (23) | 82.6 (13.7) | 58 (16.9) | 70.9 (17.4) | 80.4 (19.6) |
| Anterior Knee Pain Scale [100–0] | 74.7 (10.7) | 75.5 (13.6) | 85.5 (10.2) | 72.6 (10.8) | 79.4 (13.3) | 87.5 (9.8) |
| EQ-5D-5L index value [1–0] | 0.72 (0.1) | 0.68 (0.28) | 0.83 (0.13) | 0.71 (0.19) | 0.76 (0.13) | 0.85 (0.12) |
| EQ-5D-5L VAS [100–0] | 76.9 (15.1) | 81.6 (20.7) | 80.2 (17.7) | 81.8 (10.7) | 83 (12.6) | 88.4 (7.6) |
GROC global rating of change, KOOS Knee injury and Osteoarthritis Outcome Score, ADL activities of daily living, QoL quality of life, KOOS-PF KOOS patellofemoral subscale, VAS visual analogue scale
Square parentheses indicate possible score range, from best to worst possible score.
Number of observations: a n = 12; b n = 15; c n = 11; d n = 11.